Neoadjuvant therapy has become increasingly common in human epidermal growth factor receptor-2 (HER2)-positive breast cancer. In this study, we examined the impact of different clinicopathological characteristics on pathological complete response (pCR) in patients treated with anti-HER2 agents. The PubMed and Embase databases were searched from inception through April 2017 to identify studies that met pre-specified criteria. The odds ratios (ORs) and 95% confidence intervals (CIs) were extracted directly or were calculated with other available information. Eleven randomized controlled trials (RCTs) that involved 3,269 HER2-positive women were included in this meta-analysis. Patients with hormone receptor (HR)-negative breast cancer benefited more from anti-HER2 therapy than did patients with HR-positive tumours (OR, 2.25; 95% CI, 1.93-2.62). Furthermore, this improvement in pCR was independent of anti-HER2 agents, phase, combined chemotherapy, neoadjuvant duration, year the trials started and region where the trials were conducted. Patients with small tumours achieved greater benefits than patients with large tumours (OR, 1.25; 95% CI, 1.00-1.55). Age did not predict an additional benefit from anti-HER2 neoadjuvant treatment (OR, 1.02; 95% CI, 0.73-1.45). The impact of nodal status on pCR was dependent on the anti-HER2 agents. In conclusion, for HER2-targeted neoadjuvant treatment in breast cancer, greater benefits were achieved in patients with small HR-negative tumours compared with patients with large HR-positive tumours. These results may improve drug development and treatment strategies, economic analyses and the design and interpretation of clinical trials.
Globally, breast cancer is one of the most commonly diagnosed malignancies and is the second leading cause of cancer death in women. 1 Amplification or over-expression of human epidermal growth factor receptor 2 (HER2), which is observed in approximately 20% of breast cancers, is often associated with highly aggressive tumour behaviour and poor outcomes. 2 Accordingly, HER2 has been an important biomarker and target of therapy in breast cancer. Treatment regimens, including traditional chemotherapy agents and trastuzumab, a monoclonal antibody directly targeted against HER2, have become the standard of care in adjuvant and metastatic settings in women with HER2-positive breast cancer since 2006. 3 Currently, four anti-HER2 agents are licensed: trastuzumab, lapatinib, pertuzumab and trastuzumab emtansine. Neoadjuvant chemotherapy was once administered only to patients with locally advanced breast cancer to render large tumours operable but has since become increasingly common, particularly in the context of HER2-positive disease. 4 The response to neoadjuvant treatment offers valuable opportunities for the selection of active agents and strategies in the adjuvant phase with pathological complete response (pCR) rate as a surrogate biomarker. In fact, given that traditional drug development requires thousands of patients and many years of follow-up to reveal a significant benefit in terms of overall survival (OS), the US Food and Drug Administration (FDA) has accelerated the approval of new drugs using pCR as an endpoint in the neoadjuvant treatment of patients with high-risk early-stage breast cancer. 5 Using this endpoint, the FDA assumes that an increase in the pCR rate will translate into a clinically significant benefit in survival. Interestingly, pertuzumab, the first drug to benefit from this policy, is also a HER2-targeted agent. 6 Numerous randomized controlled trials (RCTs) have consistently demonstrated the efficacy of HER2-targeted neoadjuvant therapy. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Unfortunately, no individual randomized trials have been designed or have been adequately powered to reveal the treatment differences among women with various clinicopathological characteristics. The identification of such factors may be valuable for future clinical study design and interpretation as well as for the development of a new generation of HER2-targeted drugs. Based on accumulating evidence, in this study, we systematically evaluate the impact of four clinicopathological features, including hormone receptor (HR) status, tumour size, age and nodal status, on the efficacy of neoadjuvant treatment in patients with HER2-positive breast cancer.
Methods
This study was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.
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Literature search and study selection A comprehensive systematic search of PubMed and Embase from inception to April 2017 was performed without any language restrictions. We conducted electronic searches using exploded Medical Subject Headings (MeSH) terms and corresponding keywords. The main keywords were the following: (1) Trastuzumab, Herclon, and Herceptin; (2) Lapatinib, Lapatinib ditosylate, Tyverb, and Tykerb; (3) Pertuzumab, 2C4, and Perjeta; (4) Trastuzumab emtansine, Kadcyla; (5) Breast cancer, Breast carcinoma, Breast neoplasms, and Mammary; (6) Neoadjuvant chemotherapy and Neoadjuvant treatment and (7) Human, Clinical trial, and HER2-positive. Since recent studies of HER2-targeted agents might be unpublished, electronic searches were also conducted using the proceedings of major international congresses (San Antonio Breast Cancer Symposium, European Society of Medical Oncology and American Society of Clinical Oncology). Moreover, the reference lists of all studies that fulfilled the eligibility criteria were further examined for any relevant studies that may have been missed in the electronic searches. When multiple publications of the same clinical trial appeared or if there was a mix of cases between different publications, only the most recent study and/or the study with the most complete reporting was included.
Both inclusion and exclusion criteria were pre-specified. To be eligible, studies had to meet the following inclusion criteria: (1) population: at least 100 patients (>18 years of age) with HER2-positive breast cancer. HR status, age, nodal status, and tumour size were recorded; (2) intervention: neoadjuvant treatment with HER2-targeted regimens irrespective of dose and duration; (3) primary outcome: pathological complete response (pCR) and (4) the odds ratio (OR) and the corresponding 95% confidence interval (CI) (or data to calculate them) were reported. Other publications on the topic, including review articles, basic science papers, conference abstracts, editorials, and articles that were not specific for HER2-targeted agents, were excluded. Two authors independently conducted the initial search, screened the titles and abstracts, and classified trials as excluded, included or uncertain. Any discrepancy was resolved by consensus.
Data extraction
Outcomes of interest in this study were the impact of HR status, age, nodal status and tumour size on the efficacy of anti-HER2 neoadjuvant treatment. Identified abstracts were collected, and full texts of potentially relevant studies were reviewed for the trial design and reporting of clinical outcomes. The following items were extracted from every study: acronym of the included trial, publication year, trial phase, region, study period, main inclusion and exclusion criteria, clinical stage of breast cancer, definition of HER2-positive cancer, number of patients, anti-HER2 agent given, number of patients with HR-positive status, number of patients with HR-negative status, number of pCR events in patients with HR-positive status, number of pCR events in patients with HR-negative status, number of patients with a large tumour size, number of patients with a small tumour size, number of pCR events in patients with large tumours, number of pCR events in patients with small tumours, number of old patients, number of young patients, number of pCR events in old patients, number of pCR events in young patients, number of patients with node-positive status, number of patients with node-negative status, number of pCR events in patients with node-positive status, number of pCR events in patients with node-negative status, duration of administration, median age, follow-up duration, and outcome results of the patients. All the reviewers discussed and resolved any discrepancies in the extracted information.
Statistical analysis
The event number or percentage of pCR was reported in most studies; hence, the OR and its 95% CI were calculated using these data. In two studies, the ORs were provided directly without a corresponding event number. 10 random-effects model and a fixed-effects model were used to calculate pooled ORs, 95% CIs and p values. Statistical heterogeneity between different trials was assessed by Cochrane's Q statistic. The I 2 statistic was calculated to evaluate the extent of inconsistency that contributed to the heterogeneity across different studies. 19 The assumption of homogeneity was considered invalid for I 2 >25% and p < 0.10. To explore the potential sources of heterogeneity and to examine the influence of different exclusion standards on the overall risk estimate, pre-defined subgroup analyses were conducted. In this study, the sensitivity analysis was performed according to different anti-HER2 agents, the clinical phase, region, chemotherapy agents, duration of treatment, and year the clinical trial began. Potential publication bias was assessed by visual inspection of Begg's funnel plots, in which the log ORs were plotted against their standard errors. 20 We also conducted the Egger linear regression test and the Begg rank correlation test at a level of significance of p < 0.10.
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All analyses were performed using Stata version 12.0 (StataCorp LP, College Station, Texas). Two-sided p values <0.05 were considered statistically significant.
Results

Literature search
In all, 1,996 related studies were identified from the PubMed and Embase search, and 864 articles were duplicates and were thus excluded. After the titles and abstracts of the remaining articles were screened, 1,105 studies were removed because they did not meet the inclusion criteria. After careful review of the full texts of the remaining 27 potentially eligible papers, 11 trials were selected for the final analysis. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] A flowchart that depicts the study selection is presented in Figure 1 .
Study characteristics
As shown in Table 1 , the present meta-analysis included 11 trials of neoadjuvant chemotherapy with a total of 3,269 HER2-positive patients. Specifically, 1,810 (55%) of the patients were HR-positive, and the rest of the 1,459 subjects (45%) were HR-negative. All studies were open-label randomized trials conducted in the United States, Canada and Europe. Since all four HER2-targeted agents were developed in the past decade, these eligible trials were published between 2010 and 2015. HER2 status was verified by fluorescence in situ hybridization (FISH) and/or immunohistochemistry (IHC) in all trials. Sample size ranged from 100 to 635. The median age was between 47 and 52 years, except in one study, which did not report the age of the patients. 14 Patients in all 11 studies received both traditional chemotherapy drugs and anti-HER2 agents, and the duration of neoadjuvant treatment ranged between 16 weeks and 26 weeks.
The impact of HR status on the efficacy of trastuzumab (Tzmb) was examined in 8 trials that included 1,143 HER2-positive patients. [7] [8] [9] [11] [12] [13] [14] 17 Moreover, 654 (57%) patients were HR-positive, and 489 subjects (43%) were HR-negative.
A total of 425 pCR events occurred, 224 (53%) of which occurred in HR-positive patients, and 201 (47%) occurred in HR-negative patients. The impact of HR status on the efficacy of lapatinib (Lpnb) was examined in 5 trials that included 445 patients. 7, 8, 11, 12 In all, 245 (55%) patients were HR-positive, while the rest of the 200 subjects (45%) were HR-negative. A total of 173 pCR events occurred, 90 (52%) of which occurred in HR-positive patients, and 83 (48%) occurred in HR-negative patients. The impact of HR status on the efficacy of the combination of Tzmb and Lpnb was studied in 5 trials that included 521 patients. 7, 8, 11, 12, 14 In all, 297 (55%) patients were HR-positive, while the rest of the 224 subjects (45%) were HR-negative. A total of 297 pCR events occurred, 153 (52%) of which occurred in HR-positive patients, and 144 (48%) occurred in HR-negative patients. One study focused on pertuzumab (Pzmb) and included 96 patients; 13 50 subjects (52%) were HR-positive, and 46 (48%) were HR-negative. Two trials investigated the efficacy of the combination of Tzmb and Pzmb and included 332 patients 13, 15 164 subjects (49%) were HR-positive, and 168 (51%) were HR-negative. Two studies examined the impact of HR status on the efficacy of Tzmb or Lpnb and included 717 patients; 10, 16 400 subjects (56%) were HR-positive and 317 (44%) were HR-negative.
The impact of tumour size on the efficacy of HER2-targeted agents was investigated in 3 trials that included 1,405 HER2-positive patients. 9, 12, 14 Two studies used 4 cm as the cut-off value for the classification of large and small tumours, 9, 14 while the cut-off value in the NeoALTTO study was 5 cm. 12 In addition, 671 (48%) patients had large tumours, while the remainder of the 734 subjects (52%) had AC! T, doxorubicin hydrochloride, cyclophosphamide followed by paclitaxel; Ca, capecitabine; FEC, fluorouracil, epirubicin hydrochloride and cyclophosphamide; T, docetaxel or paclitaxel; Lpnb, lapatinib; Pzmb, pertuzumab; Tzmb, trastuzumab; NR, not reported..
small tumours. A total of 585 pCR events occurred, 264 (45%) of which occurred in women with large tumours, and 321 (55%) occurred in women with small tumours. The impact of age on the efficacy of HER2-targeted agents was examined in 3 trials that included 1,589 HER2-positive patients. 9, 14, 16 Two studies used 40 years as the cut-off value, 9, 16 while the cut-off value in the NSABP B-41 study was 50 years of age. 14 The impact of nodal status on the efficacy of HER2-targeted agents was examined in 4 trials that included 1,984 HER2-positive patients; 9,13,14,16 1,243 subjects (63%) were node positive and 741 (37%) were node negative.
Impact of HR status on pCR
Overall, the pooled model showed that patients with HRnegative breast cancer exhibited significantly more pCR events than those with HR-positive breast cancer after HER2-targeted treatment (OR, 2.25; 95% CI, 1.93-2.62; p < 0.001; fixed-effects model). No substantial heterogeneity was observed (p 5 0.28, I 2 513.6%). The advantage of pCR in HRnegative patients stratified by different anti-HER2 agents was further examined (Fig. 2a) . HR-negative patients benefited more from trastuzumab (OR, 2.13; 95% CI, 1.65-2.74), lapatinib (OR, 1.78; 95% CI, 1.18-2.68), the combination of trastuzumab and lapatinib (OR, 2.36; 95% CI, 1.63-3.43), and other types of anti-HER2 agents (OR, 2.58; 95% CI, 1.98-3.36). No statistically significant difference was observed among these subgroups (heterogeneity between subgroups, p 5 0.47), which suggested that the greater benefit achieved by HR-negative women over HR-positive women was independent of the anti-HER2 agent given.
Moreover, as shown in Figure 2b , the improvement in pCR in HR-negative patients compared with HR-positive patients did not differ by region (subgroup difference, p 5 0.34), clinical phase (subgroup difference, p 5 0.58), combined neoadjuvant chemotherapy drugs (subgroup difference, p 5 0.10), neoadjuvant duration (subgroup difference, p 5 0.50) or year the trials started (subgroup difference, p 5 0.75).
Impact of tumour size, age and nodal status on pCR
As shown in Figure 3a , the pooled model demonstrated that patients with small tumours achieved a significantly higher pCR rate than those with large tumours (OR, 1.25; 95% CI, 1.00-1.55; p 5 0.049). However, patients in different age subgroups had similar pCR rates after HER2-targeted treatment (OR, 1.02; 95% CI, 0.73-1.45; p > 0.05) (Fig. 3b) . No evidence of heterogeneity was observed for these outcomes (p 5 0.90 and 0.22, respectively). Further analyses using the randomeffects model yielded identical results.
Although the pooled model revealed that node-negative patients achieved a higher pCR rate than node-positive patients (OR, 2.97; 95% CI, 1.13-7.83), substantial heterogeneity was observed (p < 0.001, I
2 594.9%) (Fig. 3c) . Sensitivity assessments were performed to explore potential sources of heterogeneity and to examine the influence of different inclusion standards on the overall risk estimate. A subgroup analysis suggested that the impact of nodal status on pCR in HER2-positive breast cancer depended on the anti-HER2 agents used. Lapatinib treatment favoured node-positive patients (OR, 0.74; 95% CI, 0.55-0.99). In contrast, nodenegative patients benefited more from pertuzumab treatment (OR, 33.29; 95% CI, 8.60-128.80). Trastuzumab treatment also tended to favour node-negative patients, although the tendency was not statistically significant (OR, 2.72; 95% CI, 0.62-11.91). It should be noted that heterogeneity still existed in the trastuzumab and pertuzumab subgroup analyses.
Publication bias
Visual inspection of Begg's funnel plot did not identify substantial asymmetry (Figure 4) . The Egger linear regression test and the Begg rank correlation test also did not reveal evidence of publication bias in this study.
Discussion
To the best of our knowledge, this study, which includes 11 randomized trials with 3,269 women, is the first metaanalysis that examines the impacts of various clinicopathological characteristics on neoadjuvant efficacy in HER2-positive breast cancer patients. Our results showed that for HER2-targeted treatment, greater benefits were observed in patients with small, HR-negative breast cancer.
HER2-positive breast cancer is a heterogeneous disease, and approximately 50% of women with HER2-positive disease also have tumours with oestrogen receptor (ER) and/or progesterone receptor (PgR) over-expression (i.e., HR-positive) . 22, 23 Accumulating evidence suggests that HR status is associated with the nature of the cancer and therapeutic efficacy and, therefore, the clinical outcome. [22] [23] [24] However, the exact underlying biological mechanisms are still poorly understood. It is generally believed that the cross-talk between HRs and HER2 over-activated pathways plays a key role in these mechanisms, 24 especially considering that the HER2-mediated activation of the PI3K/Akt/mTOR and MAPK pathways can induce a down-regulation of both ER and PgR expression. 25 Preclinical studies of HER2-positive/ HR-positive breast cancer cell lines showed a restoration of responsiveness to lapatinib or trastuzumab with oestrogen deprivation. 26 Moreover, HER2 inhibition could enhance or restore both ER and PgR expression in HER2-positive clinical tissues collected from a lapatinib neoadjuvant trial. 27 Consistent with this hypothesis, an inverse correlation between HER2 protein/gene levels and HR levels in breast cancer was confirmed by quantitative analysis. 23 These results suggested that the down-regulation of HR levels was partly due to the over-expression of HER2 in breast cancer and that HER2-targeted treatment, at least during the onset phase, could achieve better efficacy in HR-negative, HER2-positive patients. Our results demonstrated that greater benefits were observed in HR-negative women. Moreover, the benefits were consistent across all subgroups. Considering the significant Tumour size is an important factor in cancer biology, and along with nodal status, it has traditionally been thought of as an indispensable prognostic/predictive factor for most subtypes of breast cancer. 31 In the past several decades, generalized mammographic screening has resulted in the increased detection of small cancers. 32 Some of these cancers have a rapid growth rate and exhibit aggressive clinical behaviours, despite the finding that patients with small tumours usually have a good prognosis. 32, 33 As a result, clinicians often face the dilemma of whether the potential reduction in the risk of recurrence warrants the toxic effects and risks of neoadjuvant/adjuvant treatment. In 2009, several studies found that patients with HER2-positive T1abN0M0 tumours were at a significant risk for relapse. 34, 35 These results, along with those of other studies, 36, 37 questioned the traditional view that the size of the breast tumour is correlated with survival in all subtypes of breast cancers. Currently, no explanation exists for this phenomenon, but systemic anti-HER2 therapy has been recommended for HER2-positive patients. 34 Recently, O'Sullivan and colleagues demonstrated that HER2-positive patients with a tumour size < 2 cm derived substantial benefits from adjuvant trastuzumab treatment with respect to disease-free survival (DFS) and OS 3 . Neoadjuvant treatment was originally intended for women with large tumours who wished to undergo breast-conserving surgery. Accordingly, for trials included in this meta-analysis, the clinicians used 4 cm as the cut-off value for the classification of small and large tumours. In one study (NeoALTTO), 5 cm was defined as the cut-off value. 12 Even so, our results still revealed that greater benefits were achieved in patients with smaller tumours. We believe that a more robust association between tumour size and neoadjuvant efficacy would emerge if the cut-off value was set at 2 cm. This result might also suggest that small tumour size is associated with highly aggressive behaviour in HER2-positive breast cancer.
Our meta-analysis has several strengths. First, we performed a comprehensive review and included the most upto-date published data, which means that our results are more extensive and valid than others. Moreover, due to accumulating evidence and a larger sample size, we had enhanced statistical power, which allowed us to provide more precise and reliable estimates. Second, all analyses were using both random-effect models and fixed-effects models. Both models revealed similar results, which suggested that our metaanalysis was robust. Third, the impact of HR status on pCR remained significant based on various classification criteria.
Our findings may be important for HER2-positive breast cancers in clinical practice; however, the current analysis is restricted by several limitations. First, long-term clinical outcomes in breast cancer, such as DFS and OS, are influenced by subsequent adjuvant treatments. In fact, several studies failed to demonstrate that pCR was validated as a surrogate endpoint for improved EFS and OS in breast cancer. 38, 39 Further analysis by Von Minckwitz and colleagues revealed a significant impact of pCR on the prognosis of HR-negative, HER2-positive breast cancer, but pCR was not correlated with prognosis in HR-positive, HER2-positive tumours. 38 However, an FDA-led meta-analysis demonstrated that in all patients with HER2-positive tumours, achievement of pCR was strongly associated with EFS and OS. 39 Based on these results, the strong association between pCR and long-term clinical outcome might also depend on the aggressiveness of the breast cancer subtype (i.e., ER-negative/HER2-positive).
Second, pathological complete response has been used as an endpoint in numerous trials of neoadjuvant systemic therapy for breast cancer. To date, however, there has not been a uniform definition of pCR, which has made the reporting and interpretation of data from neoadjuvant trials challenging. For example, one trial defined pCR as the absence of both in situ and invasive cancer following neoadjuvant chemotherapy, 9 whereas the other ten studies considered only the invasive component or cells in the definition. Investigators from two studies defined pCR as the absence of residual cancer in the breast and regional lymph nodes at the time of definitive surgery, 9, 17 whereas the remainder of the nine trials defined pCR as a complete response in the breast, irrespective of axillary nodal involvement.
Additional limitations include the following: (1) the number of studies included in some meta-analyses was relatively small; thus, subgroup analyses were difficult to conduct and might be less reliable. (2) The dose and duration of the anti-HER2 agents differed among studies, and related data of individuals were not available from each study, which might result in less accurate estimates of the pCR benefit. (3) Heterogeneity across studies could not be fully explained. The sensitivity analysis indicated that the meta-analyses were influenced by individual studies. Therefore, further analysis should be conducted if individual participant data are available. (4) The toxicity profile was another important factor for the selection of treatment options. However, it was highly difficult to perform an analysis to address such a concern because reports of adverse events from each subgroup were not available.
Our study has several important clinical and research implications. First, these results will be helpful for patient counselling. HER2-targeted agents are among the most expensive anti-tumour drugs in the world. They can be huge financial burdens for patients who are expected to co-pay or self-finance entirely by themselves. Under such circumstances, when a clinician has some difficulty in determining the optimal strategy to treat a specific patient, HR status may play a key role in the decision-making process. Another potential use of our studies is in drug development, as future HER2-targeting agents should enhance their antitumour activity, especially in patients with large, HR-positive tumours.
In summary, for HER2-targeted neoadjuvant treatment, greater benefits are observed in patients with small, HRnegative tumours. The efficacies of anti-HER2 agents are similar in patients of different ages, and the impact of nodal status depends on the anti-HER2 drugs used. These results have important implications for clinical trial design and interpretation, economic analysis, drug development, and treatment strategies for HER2-positive breast cancer.
